We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

5 hedge funds and large institutions have $2.58M invested in Blueprint Medicines in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 344 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

99% less funds holding

Funds holding: 354 → 5 (-349)

99.54% less ownership

Funds ownership: 99.58% → 0.04% (-100%)

100% less capital invested

Capital invested by funds: $8.24B → $2.58M (-$8.24B)

100% less funds holding in top 10

Funds holding in top 10: 29 → 0 (-29)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 344

Holders
5
Holders Change
-349
Holders Change %
-98.59%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-29
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
344
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$2.06K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$822M
2
BlackRock
BlackRock
New York
-$784M
3
PCM
Pentwater Capital Management
Florida
-$500M
4
State Street
State Street
Massachusetts
-$286M
5
UBS Group
UBS Group
Switzerland
-$278M
Name Holding Trade Value Shares
Change 		Change in
Stake
MF
26
Magnetar Financial
Illinois
– -$93.6M -730,047 Closed
EAM
27
Eventide Asset Management
Massachusetts
– -$93.4M -728,821 Closed
Renaissance Technologies
28
Renaissance Technologies
New York
– -$86.5M -674,500 Closed
Bank of America
29
Bank of America
North Carolina
– -$83M -647,487 Closed
Northern Trust
30
Northern Trust
Illinois
– -$72.9M -568,924 Closed
Charles Schwab
31
Charles Schwab
California
– -$71.9M -561,159 Closed
Fidelity Investments
32
Fidelity Investments
Massachusetts
– -$71.6M -558,960 Closed
Voloridge Investment Management
33
Voloridge Investment Management
Florida
– -$71.6M -558,768 Closed
WP
34
Woodline Partners
California
– -$68.2M -531,880 Closed
Man Group
35
Man Group
United Kingdom
– -$66.2M -516,258 Closed
Invesco
36
Invesco
Georgia
– -$65.5M -511,091 Closed
Balyasny Asset Management
37
Balyasny Asset Management
Illinois
– -$64.9M -505,957 Closed
N
38
Nuveen
North Carolina
– -$62.6M -488,612 Closed
NAM
39
Nexpoint Asset Management
Texas
– -$61.1M -476,742 Closed
Tudor Investment Corp
40
Tudor Investment Corp
Connecticut
– -$60.1M -468,623 Closed
Brown Advisory
41
Brown Advisory
Maryland
– -$58.8M -458,559 Closed
FTCM
42
First Trust Capital Management
Illinois
– -$58.5M -456,068 Closed
Wellington Management Group
43
Wellington Management Group
Massachusetts
– -$55.9M -435,976 Closed
JP Morgan Chase
44
JP Morgan Chase
New York
– -$53.6M -418,060 Closed
ClearBridge Investments
45
ClearBridge Investments
New York
– -$52M -405,708 Closed
LP
46
LMR Partners
United Kingdom
– -$50.7M -395,857 Closed
QC
47
Quadrature Capital
United Kingdom
– -$49.1M -382,677 Closed
ACA
48
Avoro Capital Advisors
New York
– -$48.1M -375,000 Closed
RAM
49
Readystate Asset Management
Illinois
– -$42.3M -329,831 Closed
WA
50
Whitebox Advisors
Minnesota
– -$39.7M -310,001 Closed
1
2
3 4 5

BPMC Hedge Fund Activity: Q3 2025 in Review

5 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2025, worth a combined $2.58M — down 100% from $8.24B a quarter earlier.

Sellers outnumbered buyers: 344 funds closed out of BPMC and 0 opened new positions — a net loss of 344 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $2.06K. The largest seller was Vanguard Group, exiting entirely with an estimated $822M sold.

  • 5 institutional investors held Blueprint Medicines (BPMC) as of Q3 2025, down from 354 in Q2 2025.
  • Funds reported $2.58M of Blueprint Medicines stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Blueprint Medicines positions in Q3 2025 and 344 closed out, a net change of -344 holders.
  • The largest Blueprint Medicines buyer in Q3 2025 was IFP Advisors, an estimated $2.06K added.
  • The largest Blueprint Medicines seller in Q3 2025 was Vanguard Group, an estimated $822M sold.

Based on aggregated 13F filings for Q3 2025.